Cancers | Free Full-Text | Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
IJMS | Free Full-Text | Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC | Scientific Reports
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program - ScienceDirect
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications - The Lancet Oncology
Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations - ScienceDirect
Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay
Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations - ScienceDirect
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer | Signal Transduction and Targeted Therapy
Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR | Biochemistry
EGFR T790M Reference Standard, mutation T790M | Genecopoeia
Epidermal growth factor receptor mutations in lung adenocarcinoma - Laboratory Investigation
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model | Oncogene
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy - Kobayashi - 2016 - Cancer Science - Wiley Online Library
Different treatment efficacies and T790M acquisition of EGFR‐TKIs on NSCLC patients with variable Del‐19 subtypes of EGFR - Wu - 2023 - International Journal of Cancer - Wiley Online Library
Cancers | Free Full-Text | Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?
COSMIC: expanding curation to highlight drug-resistant... | Posters | F1000Research
Pie chart showing the frequencies of EGFR mutations in NSCLC. Data was... | Download Scientific Diagram
Comparison of frequencies of each EGFR mutation between our survey and... | Download Table
